- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02335424
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)
A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects With Advanced/Unresectable or Metastatic Urothelial Cancer
This is a study using pembrolizumab (MK-3475, KEYTRUDA®) for first-line treatment of participants with advanced/unresectable (inoperable) or metastatic urothelial cancer who are ineligible for cisplatin-based therapy. The primary study objective is to determine the objective response rate (ORR) in all participants and by programmed cell death ligand 1 (PD-L1) status.
With Amendment 4, once a participant has achieved the study objective or the study has ended, the participant will be discontinued from this study and will be enrolled in an extension study to continue protocol-defined assessments and treatment.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically- or cytologically-confirmed diagnosis of advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra (transitional cell and mixed transitional/non-transitional cell histologies)
- Ineligible for cisplatin therapy
- No prior systemic chemotherapy for metastatic disease (adjuvant or neoadjuvant platinum-based chemotherapy with recurrence >12 months since completion of therapy is allowed)
- Available tissue from a newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
- Measurable disease
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- Adequate organ function
- Female participants of childbearing potential have a negative urine or serum pregnancy test; surgically sterile, or willing to use 2 acceptable methods of birth control, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study treatment
- Male participants must be willing to use an adequate method of contraception starting with the first dose of study medication through 120 days after the last dose of study treatment
Exclusion Criteria:
- Disease that is suitable for local therapy administered with curative intent
- Currently participating or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study treatment
- Prior anti-cancer monoclonal antibody (mAb) for direct anti-neoplastic treatment within 4 weeks prior to study Day 1 or who has not recovered from adverse events due to agents administered more than 4 weeks earlier
- Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or not recovered from AEs due to a previously administered agent
- Known additional malignancy that is progressing or requires active treatment excepting basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cancer
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Active autoimmune disease that has required systemic treatment in past 2 years
- Evidence of interstitial lung disease or active non-infectious pneumonitis
- Active infection requiring systemic therapy
- Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of study treatment
- Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another co-inhibitory T-cell receptor
- Known human immunodeficiency virus (HIV)
- Known active Hepatitis B or C
- Received a live virus vaccine within 30 days of planned start of study treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pembrolizumab
Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 2 years.
Eligible participants who stopped the initial course of pembrolizumab due to complete response (CR) or completed initial course of pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator's discretion for up to an additional year.
|
IV infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants
Time Frame: Up to approximately 80.5 months
|
ORR was determined in all participants and was defined as the percentage of participants who had a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR).
Participants with missing data were considered non-responders.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Up to approximately 80.5 months
|
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥1%
Time Frame: Up to approximately 80.5 months
|
ORR was determined in participants who had a PD-L1 CPS of ≥1% as measured by immunohistochemistry assay.
ORR was defined as the percentage of participants who had a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR).
Participants with missing data were considered non-responders.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Up to approximately 80.5 months
|
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥10%
Time Frame: Up to approximately 80.5 months
|
ORR was determined in participants who had a PD-L1 CPS of ≥10% as measured by immunohistochemistry assay.
ORR was defined as the percentage of participants who had a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR).
Participants with missing data were considered non-responders.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Up to approximately 80.5 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants
Time Frame: Up to approximately 80.5 months
|
DOR was determined in participants who demonstrated a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR).
DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death and was calculated using the product-limit (Kaplan-Meier) method for censored data.
Participants who had not progressed or died at the time of analysis were censored at the date of their last tumor assessment.
Per RECIST 1.1, PD was a ≥20% increase in the sum of diameters of target lesions plus an absolute increase of ≥5 mm in the sum, or the appearance of ≥1 new lesions.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Up to approximately 80.5 months
|
Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥1%
Time Frame: Up to approximately 80.5 months
|
DOR was determined in participants who had a PD-L1 CPS of ≥1%, as measured by immunohistochemistry assay, and had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR).
DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death and was calculated using the product-limit (Kaplan-Meier) method for censored data.
Participants who had not progressed or died at the time of analysis were censored at the date of their last tumor assessment.
Per RECIST 1.1, PD was a ≥20% increase in the sum of diameters of target lesions plus an absolute increase of ≥5 mm in the sum, or the appearance of ≥1 new lesions.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Up to approximately 80.5 months
|
Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥10%
Time Frame: Up to approximately 80.5 months
|
DOR was determined in participants who had a PD-L1 CPS of ≥10%, as measured by immunohistochemistry assay, and had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR).
DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death and was calculated using the product-limit (Kaplan-Meier) method for censored data.
Participants who had not progressed or died at the time of analysis were censored at the date of their last tumor assessment.
Per RECIST 1.1, PD was a ≥20% increase in the sum of diameters of target lesions plus an absolute increase of ≥5 mm in the sum, or the appearance of ≥1 new lesions.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Up to approximately 80.5 months
|
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants
Time Frame: Up to approximately 80.5 months
|
PFS was determined in all participants.
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first, per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR).
Per RECIST 1.1, PD was a ≥20% increase in the sum of diameters of target lesions plus an absolute increase of ≥5 mm in the sum, or the appearance of ≥1 new lesions.
Time to scheduled tumor assessment visit rather than the actual tumor assessment visit was used in the analysis.
PFS was calculated using the product-limit (Kaplan-Meier) method for censored data.
Participants were censored at the date of their last assessment.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Up to approximately 80.5 months
|
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥1%
Time Frame: Up to approximately 80.5 months
|
PFS was determined in participants who had a PD-L1 CPS of ≥1% as measured by immunohistochemistry assay.
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first, per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR).
Per RECIST 1.1, PD was a ≥20% increase in the sum of diameters of target lesions plus an absolute increase of ≥5 mm in the sum, or the appearance of ≥1 new lesions.
Time to scheduled tumor assessment visit rather than the actual tumor assessment visit was used in the analysis.
PFS was calculated using the product-limit (Kaplan-Meier) method for censored data.
Participants were censored at the date of their last assessment.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Up to approximately 80.5 months
|
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥10%
Time Frame: Up to approximately 80.5 months
|
PFS was determined in participants who had a PD-L1 CPS of ≥10% as measured by immunohistochemistry assay.
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first, per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR).
Per RECIST 1.1, PD was a ≥20% increase in the sum of diameters of target lesions plus an absolute increase of ≥5 mm in the sum, or the appearance of ≥1 new lesions.
Time to scheduled tumor assessment visit rather than the actual tumor assessment visit was used in the analysis.
PFS was calculated using the product-limit (Kaplan-Meier) method for censored data.
Participants were censored at the date of their last assessment.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Up to approximately 80.5 months
|
Overall Survival (OS) in All Participants
Time Frame: Up to approximately 80.5 months
|
OS was determined for all participants and was defined as the time from randomization to death due to any cause.
OS was calculated using the product-limit (Kaplan-Meier) method for censored data.
Participants were censored at the date of their last assessment.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Up to approximately 80.5 months
|
Overall Survival (OS) in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥1%
Time Frame: Up to approximately 80.5 months
|
OS was determined in participants who had a PD-L1 CPS of ≥1%, as measured by immunohistochemistry assay.
OS was defined as the time from randomization to death due to any cause.
OS was calculated using the product-limit (Kaplan-Meier) method for censored data.
Participants were censored at the date of their last assessment.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Up to approximately 80.5 months
|
Overall Survival (OS) in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥10%
Time Frame: Up to approximately 80.5 months
|
OS was determined in participants who had a PD-L1 CPS of ≥10% as measured by immunohistochemistry assay.
OS was defined as the time from randomization to death due to any cause.
OS was calculated using the product-limit (Kaplan-Meier) method for censored data.
Participants were censored at the date of their last assessment.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Up to approximately 80.5 months
|
Progression Free Survival Rate (PFS Rate) at Month 6 in All Participants
Time Frame: Month 6
|
The PFS rate was determined in all participants at Month 6. PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first, per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR).
Per RECIST 1.1, PD was a ≥20% increase in the sum of diameters of target lesions plus an absolute increase of ≥5 mm in the sum, or the appearance of ≥1 new lesions.
Time to scheduled tumor assessment visit rather than the actual tumor assessment visit was used in the analysis.
PFS at Month 6 was calculated using product-limit (Kaplan-Meier) method for censored data.
Participants were censored at the date of their last assessment.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Month 6
|
Progression Free Survival Rate (PFS Rate) at Month 6 in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥1%
Time Frame: Month 6
|
The PFS rate was determined in participants who had a PD-L1 CPS of ≥1%, as measured by immunohistochemistry assay, at Month 6. PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first, per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR).
Per RECIST 1.1, PD was a ≥20% increase in the sum of diameters of target lesions plus an absolute increase of ≥5 mm in the sum, or the appearance of ≥1 new lesions.
Time to scheduled tumor assessment visit rather than the actual tumor assessment visit was used in the analysis.
PFS at Month 6 was calculated using product-limit (Kaplan-Meier) method for censored data.
Participants were censored at the date of their last assessment.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Month 6
|
Progression Free Survival Rate (PFS Rate) at Month 6 in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥10%
Time Frame: Month 6
|
The PFS rate was determined in participants who had a PD-L1 CPS of ≥10%, as measured by immunohistochemistry assay, at Month 6. PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first, per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR).
Per RECIST 1.1, PD was a ≥20% increase in the sum of diameters of target lesions plus an absolute increase of ≥5 mm in the sum, or the appearance of ≥1 new lesions.
Time to scheduled tumor assessment visit rather than the actual tumor assessment visit was used in the analysis.
PFS at Month 6 was calculated using product-limit (Kaplan-Meier) method for censored data.
Participants were censored at the date of their last assessment.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Month 6
|
Progression Free Survival Rate (PFS Rate) at Month 12 in All Participants
Time Frame: Month 12
|
The PFS rate was determined in all participants at Month 12. PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first, per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR).
Per RECIST 1.1, PD was a ≥20% increase in the sum of diameters of target lesions plus an absolute increase of ≥5 mm in the sum, or the appearance of ≥1 new lesions.
Time to scheduled tumor assessment visit rather than the actual tumor assessment visit was used in the analysis.
PFS at Month 12 was calculated using product-limit (Kaplan-Meier) method for censored data.
Participants were censored at the date of their last assessment.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Month 12
|
Progression Free Survival Rate (PFS Rate) at Month 12 in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥1%
Time Frame: Month 12
|
The PFS rate was determined in participants who had a PD-L1 CPS of ≥1%, as measured by immunohistochemistry assay, at Month 12. PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first, per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR).
Per RECIST 1.1, PD was a ≥20% increase in the sum of diameters of target lesions plus an absolute increase of ≥5 mm in the sum, or the appearance of ≥1 new lesions.
Time to scheduled tumor assessment visit rather than the actual tumor assessment visit was used in the analysis.
PFS at Month 12 was calculated using product-limit (Kaplan-Meier) method for censored data.
Participants were censored at the date of their last assessment.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Month 12
|
Progression Free Survival Rate (PFS Rate) at Month 12 in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥10%
Time Frame: Month 12
|
The PFS rate was determined in participants who had a PD-L1 CPS of ≥10%, as measured by immunohistochemistry assay, at Month 12. PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first, per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR).
Per RECIST 1.1, PD was a ≥20% increase in the sum of diameters of target lesions plus an absolute increase of ≥5 mm in the sum, or the appearance of ≥1 new lesions.
Time to scheduled tumor assessment visit rather than the actual tumor assessment visit was used in the analysis.
PFS at Month 12 was calculated using product-limit (Kaplan-Meier) method for censored data.
Participants were censored at the date of their last assessment.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Month 12
|
Overall Survival Rate (OS Rate) at Month 6 in All Participants
Time Frame: Month 6
|
The OS rate was determined for all participants at Month 6 and was defined as the time from randomization to death due to any cause.
OS at Month 6 was calculated using product-limit (Kaplan-Meier) method for censored data.
Participants were censored at the date of their last assessment.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Month 6
|
Overall Survival Rate (OS Rate) at Month 6 in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥1%
Time Frame: Month 6
|
The OS rate was determined in participants who had a PD-L1 CPS of ≥1%, as measured by immunohistochemistry assay, at Month 6. OS was defined as the time from randomization to death due to any cause.
OS at Month 6 was calculated using product-limit (Kaplan-Meier) method for censored data.
Participants were censored at the date of their last assessment.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Month 6
|
Overall Survival Rate (OS Rate) at Month 6 in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥10%
Time Frame: Month 6
|
The OS rate was determined in participants who had a PD-L1 CPS of ≥10%, as measured by immunohistochemistry assay, at Month 6. OS was defined as the time from randomization to death due to any cause.
OS at Month 6 was calculated using product-limit (Kaplan-Meier) method for censored data.
Participants were censored at the date of their last assessment.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Month 6
|
Overall Survival Rate (OS Rate) at Month 12 in All Participants
Time Frame: Month 12
|
The OS rate was determined for all participants at Month 12 and was defined as the time from randomization to death due to any cause.
OS at Month 12 was calculated using product-limit (Kaplan-Meier) method for censored data.
Participants were censored at the date of their last assessment.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Month 12
|
Overall Survival Rate (OS Rate) at Month 12 in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥1%
Time Frame: Month 12
|
The OS rate was determined in participants who had a PD-L1 CPS of ≥1%, as measured by immunohistochemistry assay, at Month 12. OS was defined as the time from randomization to death due to any cause.
OS at Month 12 was calculated using product-limit (Kaplan-Meier) method for censored data.
Participants were censored at the date of their last assessment.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Month 12
|
Overall Survival Rate (OS Rate) at Month 12 in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥10%
Time Frame: Month 12
|
The OS rate was determined in participants who had a PD-L1 CPS of ≥10%, as measured by immunohistochemistry assay, at Month 12. OS was defined as the time from randomization to death due to any cause.
OS at Month 12 was calculated using product-limit (Kaplan-Meier) method for censored data.
Participants were censored at the date of their last assessment.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Month 12
|
Programmed Cell Death Ligand 1 (PD-L1) Expression Status
Time Frame: Day 1
|
PD-L1 expression status was determined as the percent of disease tumor cells, from newly obtained tumor biopsies, demonstrating plasma membrane PD-L1 staining of any intensity using an immunohistochemistry (IHC) assay.
The assay uses a Combined Positive Score (CPS) as a measure of PD-L1 positivity.
The CPS is calculated as the number of PD-L1-positive cells divided by the number of viable tumor cells analyzed multiplied by 100.
A CPS of <1% = negative; ≥1% = positive; and ≥10% = strongly positive.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Day 1
|
Number of Participants Who Experienced At Least One Adverse Event (AE)
Time Frame: Up to approximately 80.5 months
|
An AE was defined as any untoward medical occurrence in a participant administered a study treatment and did not necessarily have a causal relationship with this treatment.
An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Up to approximately 80.5 months
|
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
Time Frame: Up to approximately 26 months
|
An AE was defined as any untoward medical occurrence in a participant administered a study treatment and did not necessarily have a causal relationship with this treatment.
An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Up to approximately 26 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR) Per Modified Response Evaluation Criteria in Solid Tumors (Modified RECIST) in All Participants
Time Frame: Up to approximately 80.5 months
|
ORR was determined in all participants and was defined as the percentage of participants who had a confirmed Complete Response (CR: complete disappearance of all lesions and no new lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per modified RECIST as assessed by Blinded Independent Central Review (BICR).
Modified RECIST differs from RECIST 1.1 in that progressive disease requires confirmation by a repeat radiological assessment no less than 4 weeks from the date of first documented progressive disease.
Participants with missing data were considered non-responders.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Up to approximately 80.5 months
|
Objective Response Rate (ORR) Per Modified Response Evaluation Criteria in Solid Tumors (Modified RECIST) in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥1%
Time Frame: Up to approximately 80.5 months
|
ORR was determined in participants who had a PD-L1 CPS of ≥1% as measured by immunohistochemistry assay.
ORR was defined as the percentage of participants who had a confirmed Complete Response (CR: complete disappearance of all lesions and no new lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per modified RECIST as assessed by Blinded Independent Central Review (BICR).
Modified RECIST differs from RECIST 1.1 in that progressive disease requires confirmation by a repeat radiological assessment no less than 4 weeks from the date of first documented progressive disease.
Participants with missing data were considered non-responders.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Up to approximately 80.5 months
|
Objective Response Rate (ORR) Per Modified Response Evaluation Criteria in Solid Tumors (Modified RECIST) in Participants With a Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) of ≥10%
Time Frame: Up to approximately 80.5 months
|
ORR was determined in participants who had a PD-L1 CPS of ≥10% as measured by immunohistochemistry assay.
ORR was defined as the percentage of participants who had a confirmed Complete Response (CR: complete disappearance of all lesions and no new lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per modified RECIST as assessed by Blinded Independent Central Review (BICR).
Modified RECIST differs from RECIST 1.1 in that progressive disease requires confirmation by a repeat radiological assessment no less than 4 weeks from the date of first documented progressive disease.
Participants with missing data were considered non-responders.
Per protocol, only data generated during the initial course of treatment contributed to the analysis.
|
Up to approximately 80.5 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- van Vugt MJH, Stone JA, De Greef RHJMM, Snyder ES, Lipka L, Turner DC, Chain A, Lala M, Li M, Robey SH, Kondic AG, De Alwis D, Mayawala K, Jain L, Freshwater T. Immunogenicity of pembrolizumab in patients with advanced tumors. J Immunother Cancer. 2019 Aug 8;7(1):212. doi: 10.1186/s40425-019-0663-4.
- Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Nov;18(11):1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26.
- Vuky J, Balar AV, Castellano D, O'Donnell PH, Grivas P, Bellmunt J, Powles T, Bajorin D, Hahn NM, Savage MJ, Fang X, Godwin JL, Frenkl TL, Homet Moreno B, de Wit R, Plimack ER. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2020 Aug 10;38(23):2658-2666. doi: 10.1200/JCO.19.01213. Epub 2020 Jun 17.
- Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee JL, Fong L, Necchi A, Sternberg CN, O'Donnell PH, Powles T, Plimack ER, Bajorin DF, Balar AV, Castellano D, Choueiri TK, Culine S, Gerritsen W, Gurney H, Quinn DI, Vuky J, Vogelzang NJ, Cristescu R, Lunceford J, Saadatpour A, Loboda A, Ma J, Rajasagi M, Godwin JL, Homet Moreno B, Grivas P. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clin Cancer Res. 2022 May 13;28(10):2050-2060. doi: 10.1158/1078-0432.CCR-21-3089.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3475-052
- MK-3475-052 (Other Identifier: Merck Protocol Number)
- KEYNOTE-052 (Other Identifier: Merck)
- 2014-002206-20 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urothelial Cancer
-
Spanish Oncology Genito-Urinary GroupBristol-Myers SquibbRecruiting
-
Astellas Pharma Global Development, Inc.Merck Sharp & Dohme LLC; Seagen Inc.RecruitingUrothelial CancerUnited States, Argentina, Australia, Belgium, Canada, China, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Singapore, Spain, Switzerland, Taiwan, Thailand and more
-
Fundacion CRIS de Investigación para Vencer el...GlaxoSmithKline; Apices Soluciones S.L.; IpsenActive, not recruiting
-
Swiss Group for Clinical Cancer ResearchActive, not recruitingUrothelial CancerGermany, Switzerland
-
University of ChicagoCompletedUrothelial CancerUnited States
-
Bristol-Myers SquibbOno Pharmaceutical Co. LtdActive, not recruitingUrothelial CancerRussian Federation, United States, Brazil, Spain, Chile, Korea, Republic of, Argentina, Australia, Canada, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Japan, Mexico, Netherlands, Norway, Peru, Poland, Romania, Swed... and more
-
AstraZenecaActive, not recruitingUrothelial CancerUnited States, Belgium, Denmark, Germany, Italy, Spain, Canada, Poland, Taiwan, France, Korea, Republic of, Netherlands, United Kingdom, Brazil, Japan, Mexico, Russian Federation, Turkey, China, Austria, Australia, Israel, Portugal, G...
-
Canadian Cancer Trials GroupCelgene; Australian and New Zealand Urogenital and Prostate Cancer Trials GroupCompletedUrothelial CancerCanada, Australia
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingBladder Urothelial CancerChina
-
Gilead SciencesMerck KGaA, Darmstadt, GermanyRecruitingMetastatic Urothelial CancerItaly, United States, Korea, Republic of, Spain, Greece, France, Germany, United Kingdom, Turkey
Clinical Trials on pembrolizumab
-
University Medical Center GroningenCompleted
-
Incyte CorporationMerck Sharp & Dohme LLCCompletedMelanomaUnited States, France, Italy, United Kingdom, Spain, Belgium, Israel, Mexico, Japan, Canada, Netherlands, Sweden, Korea, Republic of, Australia, Russian Federation, Chile, Germany, Poland, Ireland, New Zealand, Denmark, Switzerland, South Africa
-
Merck Sharp & Dohme LLCCompletedMelanomaAustralia, South Africa, Spain, Sweden
-
Acerta Pharma BVMerck Sharp & Dohme LLCCompletedMetastatic Urothelial CarcinomaUnited States
-
HUYABIO International, LLC.Active, not recruitingNon Small Cell Lung CancerUnited States
-
Prof. Dr. Matthias PreusserUnknownPrimary Central Nervous System LymphomaAustria
-
Sichuan UniversityGeneplus-Beijing Co. Ltd.RecruitingNon-small Cell Lung CancerChina
-
Chinese University of Hong KongCompletedAcral Lentiginous MelanomaHong Kong
-
Yonsei UniversityNot yet recruitingMucosal Melanoma | Acral MelanomaKorea, Republic of